Pfizer (PFE) Stock Forecast & Price Target

Pfizer
Bull Case

Here are some ways that investors could benefit from investing in Pfizer Inc.:

• Pfizer Inc. offers a compelling income opportunity with a dividend yield of 6.22%, which is significantly higher than the current 10-year Treasury yield of 5%, making it an attractive option for income-focused investors seeking to outperform fixed-income returns.
• The stock is trading at $27.92, which is below the consensus price target of $28.39, suggesting that the current valuation may be conservative and leaves room for potential re-rating as the company demonstrates durable growth and stabilizes earnings after major loss-of-exclusivity events.
• Management has indicated that major headwinds such as tariffs, drug-pricing pressures, and declining COVID-19 revenue are becoming more manageable, supported by cost-cutting efforts and a larger contribution from newer therapies that help offset declining legacy-product sales.
• Pfizer Inc. has completed a key Phase 1 study for PF-07799544, advancing the experimental drug into the next stage of development, which could improve confidence in the company's post-patent-expiry growth prospects and pipeline progress.
• The company's agreement to share some additional overseas pricing revenue with the U.S. Department of Health and Human Services may reduce regulatory uncertainty and support the recovery narrative by addressing policy pressures.